Faculty Research

Many of the faculty at the Fuqua School of Business, and throughout Duke University, are recognized internationally as innovative thought leaders and researchers across the health care spectrum. In addition to Health Sector Management (HSM) and Fuqua, many hold appointments with the Duke schools of medicine, law, public policy, environment and engineering, and are affiliated with a variety of health-related organizations worldwide.

David Ridley: Supply and Demand Analysis of Priority Review Vouchers

In 2007, Congress created the priority review voucher program to encourage development of drugs for neglected diseases. Since 2007, Congress has expanded the program to include additional diseases eligible for vouchers, but authors David Ridley and Stephane A. Régnier warn …

Peter Ubel: Doctors Miss Chances to Address Patients’ Cost Concerns

Peter A. Ubel and six other colleagues undertook a qualitative study of audio-recorded clinical encounters from outpatient clinic visits for patients with breast cancer, rheumatoid arthritis, and depression. They discovered two main ways physicians fail to address their patients’ out-of-pocket …

David Ridley: Vaccine Shortages and Pricing

David Ridley, HSM Faculty Director, with co-authors Eli Liebman and Xiaoshu Bei, examined the drivers of vaccine shortages. In 2004 an Institute of Medicine report warned of vaccine shortages, raising concerns about disease outbreaks. More than a decade later, Ridley …

Peter Ubel: Reducing Healthcare Costs Through Doctor-Patient Communication

There is limited amount of information published that analyzes physician-patient cost communication during clinic visits. Published estimates of the amount of patients who discuss costs with their physicians range from 14% to 44%, and even less is known about the …

Peter Ubel: Using Copays to Promote High Value Care, Discourage Low Value Care

HSM and Fuqua School of Business professor Peter Ubel discusses the impact of a system that determines out-of-pocket expenses for patients based not on the cost of care, but on its value, defined as “healthcare outcomes achieved per dollar spent.”¹ …

David Ridley: How Drug Market Share Varies with Entry Timing and Advertising

Fuqua professor and HSM Faculty Director David Ridley, along with coauthor Stephane Régnier, estimated how a drug’s peak market share depends on its promotional spending, its order of entry into the market, and its time to the market relative to …

Barak Richman: Cost, Medicare, and Alternative Payment Models

The authors, including HSM and Duke University Law School Professor Barak Richman, examined the impact of Alternative Payment Models (APMs) in Fee-for-Service Medicare as a way to reduce expenditures in dealing with the growing Medicare population. They focused on two …

Mark McClellan & Gregory Daniel: Off-Label Oncology Drugs and Evidence Development

Drs. Mark McClellan and Gregory Daniel of the Duke-Margolis Center for Health Policy describe ways to increase evidence development for off-label drugs in oncology. They outline two pathways by which evidence development has been explored, through the ASCO TAPUR study …

Bill Boulding & Richard Staelin: Financial Health Impacts on Quality of Patient Care

Fuqua’s Dean Bill Boulding, Professor Richard Staelin, alumni Matthew Manary and Seth Glickman studied the impact of a hospital’s financial health on quality of care. Currently, the US government penalizes lower-performing hospitals with lower reimbursements, which in turn could lead …

Barak Richman: Health Systems and Antitrust Policies

In this article, Duke Law and Fuqua Professor Barak D. Richman and coauthors discuss the court ruling that disallowed Partners HealthCare in Suffolk County, MA from adding three additional providers to their health system. The publication explores the impact of …